Freeline Therapeutics to Host Full Year 2022 Financial Results Call

LONDON, March 28, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, April 4, 2023 to report its full year 2022 financial results and provide a corporate update.

To access the conference call, participants may register here. While not required, it is recommended that participants join the call 10 minutes prior to the scheduled start. A live webcast of the call will also be available on the Investors section of Freeline’s website at An archived replay of the webcast be available for approximately 90 days following the call.

About Freeline Therapeutics
Freeline is a clinical-stage biotechnology company developing transformative adeno-associated virus (AAV) vector-mediated gene therapies. The company is dedicated to improving patient lives through innovative, one-time treatments for chronic debilitating diseases. Freeline uses its proprietary, rationally designed AAV vector and capsid (AAVS3), along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing or dysfunctional protein into the patient’s bloodstream. The company is advancing clinical programs in Fabry disease and Gaucher disease Type 1. Freeline is headquartered in the UK and has operations in the United States. For more information about the company, visit or connect with Freeline on LinkedIn and Twitter.

Media and Investor Contact:
Naomi Aoki
Senior Vice President, Head of Investor Relations & Communications
+ 1 617 283 4298